List of bibliographic references
Number of relevant bibliographic references: 13.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 9 | Animals |
| 6 | Disease Models, Animal |
| 5 | Humans |
| 4 | Animal |
| 4 | Animal model |
| 4 | Parkinson disease |
| 3 | Female |
| 3 | Levodopa (adverse effects) |
| 3 | Macaca fascicularis |
| 3 | Monkey |
| 3 | Nervous system diseases |
| 3 | Parkinson Disease (etiology) |
| 3 | Parkinson Disease (genetics) |
| 2 | Amantadine (therapeutic use) |
| 2 | Antiparkinson Agents (adverse effects) |
| 2 | Dopamine Agents (adverse effects) |
| 2 | Drug Therapy, Combination |
| 2 | Dyskinesia |
| 2 | Dyskinesia, Drug-Induced (drug therapy) |
| 2 | Dyskinesia, Drug-Induced (etiology) |
| 2 | Levodopa |
| 2 | Male |
| 2 | Mice |
| 2 | Mice, Transgenic |
| 2 | Mouse |
| 2 | Mutation (genetics) |
| 2 | Parkinson Disease (drug therapy) |
| 2 | Parkinsonian Disorders (drug therapy) |
| 2 | Primates |
| 2 | Protein-Serine-Threonine Kinases (genetics) |
| 2 | alpha-Synuclein (genetics) |
| 2 | mouse |
| 1 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 1 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects) |
| 1 | 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) |
| 1 | 6‐hydroxydopamine (6‐OHDA) |
| 1 | Amphetamine (diagnostic use) |
| 1 | Analysis of Variance |
| 1 | Anticonvulsant |
| 1 | Anticonvulsants (pharmacology) |
| 1 | Anticonvulsants (therapeutic use) |
| 1 | Antiparkinson Agents (pharmacology) |
| 1 | Antiparkinson agent |
| 1 | Apomorphine (pharmacology) |
| 1 | Autophagy |
| 1 | Bacteriosis |
| 1 | Brain (metabolism) |
| 1 | Brain Mapping |
| 1 | Caenorhabditis elegans |
| 1 | Callithrix |
| 1 | Chemotherapy |
| 1 | Chorea |
| 1 | Chromosome |
| 1 | Combined treatment |
| 1 | Corpus Striatum (drug effects) |
| 1 | Corpus Striatum (pathology) |
| 1 | Corpus Striatum (physiopathology) |
| 1 | Diagnosis, Differential |
| 1 | Dopamine (metabolism) |
| 1 | Dopamine Agents (metabolism) |
| 1 | Dose-Response Relationship, Drug |
| 1 | Drosophila melanogaster |
| 1 | Drug Synergism |
| 1 | Dystonia |
| 1 | Evaluation scale |
| 1 | Excitatory Amino Acid Antagonists (therapeutic use) |
| 1 | Gaucher Disease (complications) |
| 1 | Gaucher Disease (genetics) |
| 1 | Gaucher Disease (pathology) |
| 1 | Gene Expression Regulation (drug effects) |
| 1 | Genetic Vectors (adverse effects) |
| 1 | Glucosylceramidase (genetics) |
| 1 | Glucosylceramidase (metabolism) |
| 1 | History, 20th Century |
| 1 | Human |
| 1 | Imidazoles (therapeutic use) |
| 1 | Indoles (adverse effects) |
| 1 | LRRK2 |
| 1 | Levetiracetam |
| 1 | Levodopa (pharmacology) |
| 1 | Lysosomes (metabolism) |
| 1 | Lysosomes (pathology) |
| 1 | L‐dopa |
| 1 | MPTP Poisoning (drug therapy) |
| 1 | MPTP—3 nitropropionic acid |
| 1 | Medial Forebrain Bundle (physiology) |
| 1 | Motor Activity (drug effects) |
| 1 | Multiple System Atrophy (chemically induced) |
| 1 | Multiple System Atrophy (pathology) |
| 1 | Multiple System Atrophy (physiopathology) |
| 1 | Multiple system atrophy |
| 1 | Nerve Degeneration (chemically induced) |
| 1 | Nerve Degeneration (pathology) |
| 1 | Nerve Degeneration (physiopathology) |
| 1 | Neurodegenerative Diseases (pathology) |
| 1 | Neurodegenerative Diseases (physiopathology) |
| 1 | Neuroprotective Agents (therapeutic use) |
| 1 | Neurotoxins |
| 1 | Neurotoxins (toxicity) |
| 1 | Nigrostriatal pathway |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Erwan Bezard"
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i \
-Sk "Erwan Bezard" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Erwan Bezard
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
